Chapter 2 . 1 Reduced biological activity of recombinant IFN-β and treatment response IFN-β bioactivity measurement in MS : feasibility for routine clinical practice

[1]  K. Schmierer,et al.  Assessing treatment response to interferon-β , 2014, Neurology.

[2]  Pablo Villoslada,et al.  Multiple Sclerosis Susceptibility Genes: Associations with Relapse Severity and Recovery , 2013, PloS one.

[3]  J. Havla,et al.  Bridging, switching or drug holidays – how to treat a patient who stops natalizumab? , 2013, Therapeutics and clinical risk management.

[4]  P. Calabresi,et al.  Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. , 2013, Brain : a journal of neurology.

[5]  Hans-Jürgen Thiesen,et al.  MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients , 2013, International journal of molecular sciences.

[6]  R. Reuss.  PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update , 2013, Biologics : targets & therapy.

[7]  T. Olsson,et al.  Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity , 2013, Proceedings of the National Academy of Sciences.

[8]  F. Barkhof,et al.  Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis , 2013, Multiple sclerosis.

[9]  L. Steinman,et al.  Type I Interferons: Beneficial in Th1 and Detrimental in Th17 Autoimmunity , 2013, Clinical Reviews in Allergy & Immunology.

[10]  M. Kvarnström,et al.  Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13 , 2013, Journal of the Neurological Sciences.

[11]  G. Esendagli,et al.  Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy , 2013, Journal of Neuroimmunology.

[12]  S. Dhib-jalbut,et al.  Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study , 2013, Journal of Neuroimmunology.

[13]  A. Vulto,et al.  Interchangeability, immunogenicity and biosimilars , 2012, Nature Biotechnology.

[14]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[15]  F. Deisenhammer,et al.  Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial , 2012, Neurology.

[16]  L. Steinman,et al.  Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS , 2012, Neurology.

[17]  Bernhard Hemmer,et al.  Potassium channel KIR4.1 as an immune target in multiple sclerosis. , 2012, The New England journal of medicine.

[18]  H. Wiendl,et al.  Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort , 2012, Neurology.

[19]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[20]  J. Hillert,et al.  Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice , 2012, Multiple sclerosis.

[21]  A. Lutterotti,et al.  Persistency of neutralizing antibodies depends on titer and interferon-beta preparation , 2012, Multiple sclerosis.

[22]  Joanne L. Jones,et al.  Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis , 2012, Expert review of neurotherapeutics.

[23]  A. Reder,et al.  Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis , 2012, Journal of the Neurological Sciences.

[24]  D. Goodin,et al.  Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial , 2012, Multiple sclerosis.

[25]  X. Montalban,et al.  Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. , 2011, Clinical immunology.

[26]  D. Paty,et al.  Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial , 2011, Neurology.

[27]  A. P. Ross,et al.  Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis , 2011, International journal of clinical practice.

[28]  C. Polman,et al.  IL-7 Promotes TH1 Development and Serum IL-7 Predicts Clinical Response to Interferon-β in Multiple Sclerosis , 2011, Science Translational Medicine.

[29]  L. Steinman,et al.  Interferon-β exacerbates Th17-mediated inflammatory disease. , 2011, Trends in immunology.

[30]  M. Sá,et al.  Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. , 2011, Arquivos de neuro-psiquiatria.

[31]  R. Rudick,et al.  Excessive Biologic Response to IFNβ Is Associated with Poor Treatment Response in Patients with Multiple Sclerosis , 2011, PloS one.

[32]  A. Bertolotto,et al.  One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients , 2011, Journal of Neurology.

[33]  H. Lockstone,et al.  IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses , 2011, Nature Immunology.

[34]  P. Sørensen,et al.  Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab , 2011, Neurology.

[35]  P. Van Der Valk,et al.  Multiple sclerosis as an “Inside‐out” disease , 2010, Annals of neurology.

[36]  F. Barkhof,et al.  Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS , 2010, Neurology.

[37]  K. Vandenbroeck,et al.  Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[38]  H. Hartung,et al.  Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. , 2010, Archives of neurology.

[39]  M. Bojar,et al.  Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis , 2010, Multiple sclerosis.

[40]  M. Crow.  Type I interferon in organ-targeted autoimmune and inflammatory diseases , 2010, Arthritis research & therapy.

[41]  E. Urcelay,et al.  IFN-beta pharmacogenomics in multiple sclerosis. , 2010, Pharmacogenomics.

[42]  Jacqueline A Palace,et al.  Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. , 2010, Archives of neurology.

[43]  Bernhard Hemmer,et al.  Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis , 2010, The Lancet Neurology.

[44]  S. Gregory,et al.  Alternative splicing in multiple sclerosis and other autoimmune diseases , 2010, RNA biology.

[45]  G. Giovannoni,et al.  Multiple sclerosis: risk factors, prodromes, and potential causal pathways , 2010, The Lancet Neurology.

[46]  G. Ebers,et al.  Multiple sclerosis, vitamin D, and HLA-DRB1*15 , 2010, Neurology.

[47]  AJ Thompson,et al.  Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? , 2010, Multiple sclerosis.

[48]  H. Søndergaard,et al.  Breakthrough disease during interferon-β therapy in MS , 2010, Neurology.

[49]  G. Gronseth,et al.  Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis , 2010, Neurology.

[50]  David Arteta,et al.  Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis , 2010, Multiple sclerosis.

[51]  M. Brown,et al.  Multiple Sclerosis Susceptibility-Associated SNPs Do Not Influence Disease Severity Measures in a Cohort of Australian MS Patients , 2010, PloS one.

[52]  Lawrence Steinman,et al.  T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis , 2010, Nature Medicine.

[53]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[54]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[55]  F. Barkhof,et al.  MRI criteria for MS in patients with clinically isolated syndromes , 2010, Neurology.

[56]  A. Lovett-racke,et al.  The mechanism of action of glatiramer acetate treatment in multiple sclerosis , 2010, Neurology.

[57]  R. Rudick,et al.  Gray-matter injury in multiple sclerosis. , 2009, New England Journal of Medicine.

[58]  A. Svejgaard,et al.  Identification of new sensitive biomarkers for the in vivo response to interferon‐β treatment in multiple sclerosis using DNA‐array evaluation , 2009, European journal of neurology.

[59]  X. Montalban,et al.  A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. , 2009, Brain : a journal of neurology.

[60]  S. Ropele,et al.  Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study , 2009, Multiple sclerosis.

[61]  C. Pozzilli,et al.  One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis , 2009, European journal of neurology.

[62]  M. Freedman.  ‘Time is brain’ also in multiple sclerosis , 2009, Multiple sclerosis.

[63]  Wei Hu,et al.  The pathological spectrum of CNS inflammatory demyelinating diseases , 2009, Seminars in Immunopathology.

[64]  F. Sellebjerg,et al.  Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity , 2009, Neurology.

[65]  Arcadi Navarro,et al.  Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. , 2009, Archives of neurology.

[66]  J. Grutters,et al.  Variation in IL7R predisposes to sarcoid inflammation , 2009, Genes and Immunity.

[67]  J Sastre-Garriga,et al.  Measures in the first year of therapy predict the response to interferon β in MS , 2009, Multiple sclerosis.

[68]  Ludwig Kappos,et al.  Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci , 2009, Nature Genetics.

[69]  E. Urcelay,et al.  Glypican 5 is an interferon-beta response gene: a replication study , 2009, Multiple sclerosis.

[70]  A. Sadovnick,et al.  Risk alleles for multiple sclerosis in multiplex families , 2009, Neurology.

[71]  A. Millonig,et al.  High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study , 2009, Multiple sclerosis.

[72]  R. Gold,et al.  Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. , 2009, Journal of autoimmunity.

[73]  Michael R. Johnson,et al.  Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. , 2009, Human molecular genetics.

[74]  J. Frederiksen,et al.  Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon‐β , 2009, European journal of neurology.

[75]  M. Ramanathan,et al.  Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients , 2008, Journal of Neuroimmunology.

[76]  J. Oger,et al.  The implications of immunogenicity for protein-based multiple sclerosis therapies , 2008, Journal of the Neurological Sciences.

[77]  C. Duijn,et al.  Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis , 2008, Nature Genetics.

[78]  A. Alcina,et al.  The T244I variant of the interleukin-7 receptor-alpha gene and multiple sclerosis. , 2008, Tissue antigens.

[79]  P. Sørensen,et al.  Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies? , 2008, Multiple sclerosis.

[80]  À. Rovira,et al.  Very early scans for demonstrating dissemination in time in multiple sclerosis , 2008, Multiple Sclerosis.

[81]  E. Pérez-Pampín,et al.  Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[82]  R. Lucas.  Faculty Opinions recommendation of Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. , 2008 .

[83]  C. Polman,et al.  Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients , 2008, PloS one.

[84]  P. Valentino,et al.  Predictive markers for response to interferon therapy in patients with multiple sclerosis , 2008, Neurology.

[85]  F. Holsboer,et al.  Variant form of STAT4 is associated with primary Sjögren's syndrome , 2008, Genes and Immunity.

[86]  Pablo Villoslada,et al.  Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. , 2008, Archives of neurology.

[87]  L. Peltonen,et al.  Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations , 2008, Journal of Medical Genetics.

[88]  K. Vandenbroeck,et al.  IL7RA polymorphisms and susceptibility to multiple sclerosis. , 2008, The New England journal of medicine.

[89]  À. Rovira,et al.  Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients , 2008, Multiple sclerosis.

[90]  P. Carrieri,et al.  Interleukin-10 and Interleukin-12 Modulation in Patients with Relapsing-Remitting Multiple Sclerosis on Therapy with Interferon-beta 1a: Differences in Responders and Non Responders , 2008, Immunopharmacology and immunotoxicology.

[91]  L. Milani,et al.  An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. , 2007, Human molecular genetics.

[92]  J. Haselkorn,et al.  Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model , 2007, Multiple sclerosis.

[93]  A. Pachner.  Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2007, Neurology.

[94]  J. Hillert,et al.  In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[95]  Silke Schmidt,et al.  Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis , 2007, Nature Genetics.

[96]  M. Chiarini,et al.  IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays , 2007, Journal of Neuroimmunology.

[97]  S. Gabriel,et al.  Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.

[98]  Marco Rovaris,et al.  MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study , 2007, The Lancet Neurology.

[99]  A. Syvänen,et al.  Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[100]  A. Noronha,et al.  Guidelines on use of anti‐IFN‐B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐B antibodies in multiple sclerosis , 2007, European journal of neurology.

[101]  Ludwig Kappos,et al.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.

[102]  L. Kappos,et al.  MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS , 2007, Neurology.

[103]  A. Bertolotto,et al.  Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. , 2007, Journal of immunological methods.

[104]  D. Goodin,et al.  Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED] , 2007, Neurology.

[105]  K. Honda,et al.  Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. , 2007, Biochemical and biophysical research communications.

[106]  M. Krumbholz,et al.  Multiple sclerosis: Relating MxA transcription to anti-interferon-β-neutralizing antibodies , 2007, Neurology.

[107]  M. Suoniemi,et al.  Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity , 2007, Multiple sclerosis.

[108]  K. Bendtzen,et al.  Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis? , 2007, Multiple sclerosis.

[109]  G. Giovannoni,et al.  Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis , 2007, Multiple sclerosis.

[110]  P. Sørensen,et al.  Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS , 2006, Neurology.

[111]  L. Kappos,et al.  Infusion-related hypersensitivity reactions during natalizumab treatment , 2006, Neurology.

[112]  P. Sørensen.  Neutralising antibodies to interferon-β–measurement, clinical relevance, and management , 2006, Journal of Neurology.

[113]  W. Valdar,et al.  Sex ratio of multiple sclerosis in Canada: a longitudinal study , 2006, The Lancet Neurology.

[114]  H. Link,et al.  Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.

[115]  H P Hartung,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[116]  P. Sørensen,et al.  Persistence of neutralizing antibodies after discontinuation of IFNβ therapy in patients with relapsing-remitting multiple sclerosis , 2006, Multiple sclerosis.

[117]  A. Lutterotti,et al.  Interferon-β antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies , 2006, Journal of Neuroimmunology.

[118]  Marta E Alarcón-Riquelme,et al.  A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus , 2006, Nature Genetics.

[119]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[120]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[121]  V. Tomassini,et al.  Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis , 2006, Journal of Neurology.

[122]  K. Narayan,et al.  Multiplex analysis of expression of three IFNβ-induced genes in antibody-positive MS patients , 2006, Neurology.

[123]  X. Montalban,et al.  Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[124]  A. Bertolotto,et al.  Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1 , 2006, Multiple sclerosis.

[125]  A. Bertolotto,et al.  Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments , 2005, Neurological Sciences.

[126]  V. Tomassini,et al.  Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience , 2005, Neurological Sciences.

[127]  Michael Hutchinson,et al.  Pharmacogenomics of responsiveness to interferon IFN‐β treatment in multiple sclerosis: A genetic screen of 100 type I interferon‐inducible genes , 2005, Clinical pharmacology and therapeutics.

[128]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[129]  T. Decker,et al.  The Yin and Yang of type I interferon activity in bacterial infection , 2005, Nature Reviews Immunology.

[130]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[131]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[132]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[133]  A. Thompson,et al.  The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis , 2005, Journal of Neurology.

[134]  P. Sørensen,et al.  Appearance and disappearance of neutralizing antibodies during interferon-beta therapy , 2005, Neurology.

[135]  L. Kappos,et al.  Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. , 2005 .

[136]  Katherine E. M. Hoops,et al.  Two Discrete Promoters Regulate the Alternatively Spliced Human Interferon Regulatory Factor-5 Isoforms , 2005, Journal of Biological Chemistry.

[137]  J. Kere,et al.  Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. , 2005, American journal of human genetics.

[138]  A. Bertolotto,et al.  Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis , 2005, Journal of Neuroimmunology.

[139]  A. Lutterotti,et al.  Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity , 2004, Multiple sclerosis.

[140]  F. Barkhof,et al.  Gender-related association between the TGFB1+869 polymorphism and multiple sclerosis. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[141]  A. Bertolotto,et al.  Cotugno and cerebrospinal fluid , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[142]  A. Bertolotto,et al.  Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis , 2004, Neurology.

[143]  H. Schellekens,et al.  Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis , 2004, Journal of Neurology.

[144]  M. Calabrese,et al.  The clinical impact of interferon beta antibodies in relapsing-remitting MS , 2004, Journal of Neurology.

[145]  D. Goodin,et al.  The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. , 2004, Neurology.

[146]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[147]  W. Haupt,et al.  Long‐term persisting interferon beta‐1b neutralizing antibodies after discontinuation of treatment , 2004, Acta neurologica Scandinavica.

[148]  Jingwu Z. Zhang,et al.  Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. , 2003, Brain : a journal of neurology.

[149]  M. Sela,et al.  Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy , 2003, Multiple sclerosis.

[150]  A. Pachner.  An improved ELISA for screening for neutralizing anti-IFN-β antibodies in MS patients , 2003, Neurology.

[151]  K. Bendtzen.  [Immunogenicity of biopharmaceuticals. Experiences with beta-interferon, EPO and anti-TNF]. , 2003, Ugeskrift for læger.

[152]  V. Tomassini,et al.  Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years , 2003, Journal of the Neurological Sciences.

[153]  G. Giovannoni.  Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies , 2003, Neurology.

[154]  P. Sørensen,et al.  Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis , 2003, The Lancet.

[155]  S. Vukusic,et al.  Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.

[156]  C. Pozzilli,et al.  Pharmacological methods to overcome IFN-β antibody formation in the treatment of multiple sclerosis , 2003, Expert opinion on investigational drugs.

[157]  S. Grossberg,et al.  Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. , 2003, Journal of immunological methods.

[158]  L. Staudt,et al.  Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.

[159]  A. Thompson,et al.  New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes , 2003, Annals of neurology.

[160]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[161]  J. Haines,et al.  HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. , 2003, American journal of human genetics.

[162]  R. Lindberg,et al.  Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients , 2003, Neurology.

[163]  J. Wolinsky.  The diagnosis of primary progressive multiple sclerosis , 2003, Journal of the Neurological Sciences.

[164]  Ash A. Alizadeh,et al.  Individuality and variation in gene expression patterns in human blood , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[165]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[166]  H. Hartung,et al.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.

[167]  F. Munschauer,et al.  Neutralising antibodies to interferon beta during the treatment of multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[168]  Carlos Nos,et al.  Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials , 2002, Annals of neurology.

[169]  Andreas Radbruch,et al.  Humoral immunity and long-lived plasma cells. , 2002, Current opinion in immunology.

[170]  David H. Miller,et al.  Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis , 2002, Annals of neurology.

[171]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[172]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[173]  S. Sawcer,et al.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[174]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[175]  A. Castelló,et al.  Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. , 2001, Journal of immunological methods.

[176]  S. Grossberg,et al.  The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[177]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[178]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[179]  M. Sela,et al.  Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone® , 2001, Journal of Neuroimmunology.

[180]  Polman,et al.  Drug treatment of multiple sclerosis , 2000, The Western journal of medicine.

[181]  C Confavreux,et al.  Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.

[182]  S. Cole,et al.  Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. , 2000, Neurology.

[183]  C. Eckert,et al.  Expression analysis and characterization of alternatively spliced transcripts of human IL-7Ralpha chain encoding two truncated receptor proteins in relapsed childhood all. , 2000, Cytokine.

[184]  K. Rajewsky,et al.  Memory B-cell persistence is independent of persisting immunizing antigen , 2000, Nature.

[185]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[186]  J. Hillert,et al.  HLA‐DR15 is associated with lower age at onset in multiple sclerosis , 2000, Annals of neurology.

[187]  R. Mutani,et al.  Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. , 2000, Immunopharmacology.

[188]  M. Reindl,et al.  A comparative study of the relative bioavailability of different interferon beta preparations , 2000, Neurology.

[189]  S. Cole,et al.  Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS , 2000, Neurology.

[190]  À. Rovira,et al.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[191]  F. Heidenreich,et al.  Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS , 2000, Neurology.

[192]  M. Hernán,et al.  Geographic variation of MS incidence in two prospective studies of US women , 1999, Neurology.

[193]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[194]  M. Reindl,et al.  Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies , 1999, Neurology.

[195]  D. Paty,et al.  The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b , 1999, Neurology.

[196]  R. Herndon,et al.  Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis , 1998, Neurology.

[197]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[198]  J. Petkau,et al.  Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis , 1997, Multiple sclerosis.

[199]  G. Comi,et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.

[200]  R. Priore,et al.  Mechanism(S) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. , 1997, Research communications in molecular pathology and pharmacology.

[201]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[202]  C. Pozzilli,et al.  Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome , 1997, Journal of Neurology.

[203]  L. Platanias,et al.  Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. , 1996, The Journal of biological chemistry.

[204]  D. Hinds,et al.  A full genome search in multiple sclerosis , 1996, Nature Genetics.

[205]  L Steinman,et al.  Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.

[206]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[207]  J. Kurtzke,et al.  MS epidemiology world wide. One view of current status , 1995, Acta neurologica Scandinavica. Supplementum.

[208]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs , 1994, Journal of the Neurological Sciences.

[209]  G J Barker,et al.  Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.

[210]  F. Finkelman,et al.  Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. , 1993, Journal of immunology.

[211]  K. Melén,et al.  Control of IFN-inducible MxA gene expression in human cells. , 1993, Journal of immunology.

[212]  B E Kendall,et al.  The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. , 1991, Brain : a journal of neurology.

[213]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[214]  T. Taniguchi,et al.  Organization of the murine and human interleukin-7 receptor genes: two mRNAs generated by differential splicing and presence of a type I-interferon-inducible promoter , 1991, Molecular and cellular biology.

[215]  W. Mcdonald,et al.  The longstanding MS lesion. A quantitative MRI and electron microscopic study. , 1991, Brain : a journal of neurology.

[216]  O. Turriziani,et al.  Neutralizing Antibodies to Interferon-α: Relative Frequency in Patients Treated with Different Interferon Preparations , 1991, The Journal of infectious diseases.

[217]  D. Goodkin,et al.  EDSS reliability , 1991, Neurology.

[218]  B E Kendall,et al.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.

[219]  D. Li,et al.  Chronic progressive multiple sclerosis: Serial magnetic resonance brain imaging over six months , 1989, Annals of neurology.

[220]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[221]  D. Li,et al.  Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.

[222]  V. Kostulas,et al.  Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. , 1987, Archives of neurology.

[223]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[224]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[225]  P. Sehgal.  The interferon genes. , 1982, Biochimica et biophysica acta.

[226]  H. M. Baum,et al.  The incidence and prevalence of reported multiple sclerosis , 1981, Annals of neurology.

[227]  D. Burke,et al.  Studies on the production, mode of action and properties of interferon. , 1957, British journal of experimental pathology.

[228]  S. Gregory,et al.  Cleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6. , 2013, RNA.

[229]  H. Hartung,et al.  Disease-Modifying Agents for Multiple Sclerosis , 2012, Drugs.

[230]  E. Urcelay,et al.  Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection , 2011, Genes and Immunity.

[231]  O. Kantarci.  Genotype–Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures , 2009 .

[232]  O. Kantarci.  HLA-DRB1*0401 and HLA-DRB1*0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis , 2009 .

[233]  S J Nelson,et al.  Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. , 2009, Brain : a journal of neurology.

[234]  D. Booth,et al.  Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis , 2008, Genes and Immunity.

[235]  A. Verma.  The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL , 2008 .

[236]  L. Kappos,et al.  Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. , 2007, Journal of neuroimmunology.

[237]  L. Kappos,et al.  Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. , 2007, Journal of neurology.

[238]  H. Harbo,et al.  Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. , 2007, Nature genetics.

[239]  M. Ramanathan,et al.  Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. , 2006, Journal of neuroimmunology.

[240]  K. Narayan,et al.  The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. , 2005, Journal of neuroimmunology.

[241]  K. Shinohara,et al.  Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure. , 2005, American journal of hematology/oncology.

[242]  R. Rudick,et al.  Defining interferon beta response status in multiple sclerosis patients. , 2004, Annals of neurology.

[243]  K. Zoon,et al.  Human interferons alpha, beta and omega. , 2004, Growth factors.

[244]  Hompson,et al.  A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS , 2002 .

[245]  P. Gallo,et al.  Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. , 2001, European cytokine network.

[246]  K. Bendtzen,et al.  Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. , 2000, Annals of neurology.

[247]  D. Chitayat,et al.  A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. , 2000, Blood.

[248]  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. , 1998, Lancet.

[249]  A. Whitty,et al.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). , 1998, Pharmaceutical research.

[250]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[251]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.